{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:10:22Z","timestamp":1792059022665,"version":"4.4.0"},"reference-count":27,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T00:00:00Z","timestamp":1597536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Evaluate the safety and tolerability of oral rimegepant when used for acute treatment concomitantly with a monoclonal antibody (mAb) targeting the calcitonin gene\u2010related peptide (CGRP) ligand or receptor (CGRP mAb) for the preventive treatment of migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The efficacy of CGRP mAbs for the preventive treatment of migraine and the small molecule CGRP receptor antagonist rimegepant for acute treatment has been demonstrated in randomized controlled clinical trials. Over the past few years, the US Food and Drug Administration has approved 4 CGRP mAbs for the preventive treatment of migraine and 2 small molecule CGRP receptor antagonists for the acute treatment of migraine. A previous case report of 2 patients receiving concomitant treatment with rimegepant and erenumab suggested that rimegepant may be safely used as acute treatment in patients who are also receiving a preventive regimen involving CGRP mAbs. We report here 13 additional patients with migraine who simultaneously used rimegepant and either erenumab, fremanezumab, or galcanezumab and assess the rate of on\u2010treatment adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a substudy nested within a multicenter, open\u2010label, long\u2010term safety study in adults with 2\u201014 monthly migraine attacks of moderate to severe pain intensity. A subgroup experiencing 2\u20108 monthly attacks and taking a stable dose of a CGRP mAb also took rimegepant 75\u00a0mg as needed up to once daily for acute treatment for 12\u00a0weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 13 patients (11 women [85%]; mean age 49.9\u00a0years) enrolled in the substudy were being treated with CGRP mAbs (erenumab [n\u00a0=\u00a07], fremanezumab [n\u00a0=\u00a04], or galcanezumab [n\u00a0=\u00a02]). Mean (SD) time in the rimegepant treatment period was 9.6 (4.6) weeks. Mean (SD) 4\u2010week rimegepant exposure was 7.8 (5.5) doses; a total of 224 doses were taken. Five (38%) patients reported \u22651 on\u2010treatment AE. Of these, 2 (15%) patients had mild or moderate nasopharyngitis; no other AEs occurred in \u22652 patients. Three patients had AEs of mild or moderate severity that were considered potentially treatment\u2010related. No patients had serious AEs, AEs leading to discontinuation, or aminotransferase levels &gt;3\u00d7 the upper limit of normal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rimegepant, when used as an oral acute treatment in patients receiving CGRP mAbs as preventive treatment, was well tolerated; no safety issues were identified. Studies involving larger patient populations are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.13930","type":"journal-article","created":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T11:53:30Z","timestamp":1597578810000},"page":"1734-1742","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine"],"prefix":"10.1111","volume":"60","author":[{"given":"Gary","family":"Berman","sequence":"first","affiliation":[{"name":"Clinical Research Institute Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Croop","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kudrow","sequence":"additional","affiliation":[{"name":"California Medical Clinic for Headache Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Halverson","sequence":"additional","affiliation":[{"name":"Clinical Research Institute Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Lovegren","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra C.","family":"Thiry","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Conway","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Coric","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.8.813"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410230214"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330109"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413500727"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_2_9_16_1","volume-title":"FDA Approves New Treatment for Adults With Migraine","author":"US Food and Drug Administration"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008944"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"e_1_2_9_19_1","volume-title":"Common Technical Criteria for Adverse Events (CTCAE) Version 5.0 (2017)","author":"National Cancer Institute"},{"key":"e_1_2_9_20_1","volume-title":"Table for Grading the Severity of Adult and Pediatric Adverse Events (Corrected Version 2.1, July 2017)","author":"Division of AIDS"},{"key":"e_1_2_9_21_1","volume-title":"Nurtec ODT (rimegepant) Orally Disintegrating Tablets Prescribing Information"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.07.015"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1292251"},{"key":"e_1_2_9_24_1","volume-title":"Aimovig (erenumab\u2010aooe) Injection Prescribing Information"},{"key":"e_1_2_9_25_1","volume-title":"Ajovy (fremanezumab\u2010vfrm) Injection Prescribing Information"},{"key":"e_1_2_9_26_1","volume-title":"Emgality (galcanezumab\u2010gnlm) Injection Prescribing Information"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419840780"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01633-3"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhead.13930","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13930","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.13930","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:27:12Z","timestamp":1762072032000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.13930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,16]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/head.13930"],"URL":"https:\/\/doi.org\/10.1111\/head.13930","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,16]]},"assertion":[{"value":"2020-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}